Applicability of liquid biopsies to represent the mutational profile of tumor tissue from different cancer entities.
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
22
12
2020
accepted:
24
06
2021
revised:
18
06
2021
pubmed:
8
7
2021
medline:
30
12
2021
entrez:
7
7
2021
Statut:
ppublish
Résumé
Genetic investigation of tumor heterogeneity and clonal evolution in solid cancers could be assisted by the analysis of liquid biopsies. However, tumors of various entities might release different quantities of circulating tumor cells (CTCs) and cell-free DNA (cfDNA) into the bloodstream, potentially limiting the diagnostic potential of liquid biopsy in distinct tumor histologies. Patients with advanced colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC), and melanoma (MEL) were enrolled in the study, representing tumors with different metastatic patterns. Mutation profiles of cfDNA, CTCs, and tumor tissue were assessed by panel sequencing, targeting 327 cancer-related genes. In total, 30 tissue, 18 cfDNA, and 7 CTC samples from 18 patients were sequenced. Best concordance between the mutation profile of tissue and cfDNA was achieved in CRC and MEL, possibly due to the remarkable heterogeneity of HNSCC (63%, 55% and 11%, respectively). Concordance especially depended on the amount of cfDNA used for library preparation. While 21 of 27 (78%) tissue mutations were retrieved in high-input cfDNA samples (30-100 ng, N = 8), only 4 of 65 (6%) could be detected in low-input samples (<30 ng, N = 10). CTCs were detected in 13 of 18 patients (72%). However, downstream analysis was limited by poor DNA quality, allowing targeted sequencing of only seven CTC samples isolated from four patients. Only one CTC sample reflected the mutation profile of the respective tumor. Private mutations, which were detected in CTCs but not in tissue, suggested the presence of rare subclones. Our pilot study demonstrated superiority of cfDNA- compared to CTC-based mutation profiling. It was further shown that CTCs may serve as additional means to detect rare subclones possibly involved in treatment resistance. Both findings require validation in a larger patient cohort.
Identifiants
pubmed: 34230613
doi: 10.1038/s41388-021-01928-w
pii: 10.1038/s41388-021-01928-w
pmc: PMC8376638
doi:
Substances chimiques
Cell-Free Nucleic Acids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5204-5212Informations de copyright
© 2021. The Author(s).
Références
Kidess E, Jeffrey SS. Circulating tumor cells versus tumor-derived cell-free DNA: rivals or partners in cancer care in the era of single-cell analysis? Genome Med. 2013;5:70.
pubmed: 23953663
pmcid: 3979136
doi: 10.1186/gm474
Prasetyanti PR, Medema JP. Intra-tumor heterogeneity from a cancer stem cell perspective. Mol Cancer. 2017;16:41.
pubmed: 28209166
pmcid: 5314464
doi: 10.1186/s12943-017-0600-4
Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–92.
pubmed: 22397650
pmcid: 4878653
doi: 10.1056/NEJMoa1113205
Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer. 2013;108:479–85.
pubmed: 23299535
pmcid: 3593543
doi: 10.1038/bjc.2012.581
Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532–6.
pubmed: 22722830
pmcid: 3927413
doi: 10.1038/nature11156
Martelotto LG, Ng CKY, Piscuoglio S, Weigelt B, Reis-Filho JS. Breast cancer intra-tumor heterogeneity. Breast Cancer Res. 2014;16:210.
pubmed: 25928070
pmcid: 4053234
doi: 10.1186/bcr3658
Castro-Giner F, Aceto N. Tracking cancer progression: from circulating tumor cells to metastasis. Genome Med. 2020;12:31.
pubmed: 32192534
pmcid: 7082968
doi: 10.1186/s13073-020-00728-3
Tayoun T, Faugeroux V, Oulhen M, Aberlenc A, Pawlikowska P, Farace F. CTC-derived models: a window into the seeding capacity of circulating tumor cells (CTCs). Cells. 2019;8:1145.
Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF, et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol. 1998;153:865–73.
pubmed: 9736035
pmcid: 1853000
doi: 10.1016/S0002-9440(10)65628-3
Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Onco. 2014;32:579–86.
doi: 10.1200/JCO.2012.45.2011
Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21:795–801.
pubmed: 26030179
pmcid: 4868598
doi: 10.1038/nm.3870
Khan KH, Cunningham D, Werner B, Vlachogiannis G, Spiteri I, Heide T, et al. Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. Cancer Discov. 2018;8:1270–85.
pubmed: 30166348
pmcid: 6380469
doi: 10.1158/2159-8290.CD-17-0891
Kuhlmann JD, Wimberger P, Bankfalvi A, Keller T, Schöler S, Aktas B, et al. ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance. Clin Chem. 2020;60:1282–9.
doi: 10.1373/clinchem.2014.224808
Fernandez-Garcia D, Hills A, Page K, Hastings RK, Toghill B, Goddard KS, et al. Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer. Breast Cancer Res. 2019;21:149.
pubmed: 31856868
pmcid: 6924016
doi: 10.1186/s13058-019-1235-8
Grisanti S, Almici C, Consoli F, Buglione M, Verardi R, Bolzoni-Villaret A, et al. Circulating tumor cells in patients with recurrent or metastatic head and neck carcinoma: prognostic and predictive significance. PLoS One. 2014;9:e103918.
pubmed: 25105871
pmcid: 4126745
doi: 10.1371/journal.pone.0103918
Oellerich M, Schütz E, Beck J, Walson PD. Circulating cell-free DNA-diagnostic and prognostic applications in personalized cancer therapy. Ther Drug Monit. 2019;41:115–20.
pubmed: 30883505
doi: 10.1097/FTD.0000000000000566
Gray ES, Rizos H, Reid AL, Boyd SC, Pereira MR, Lo J, et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget. 2015;6:42008–18.
pubmed: 26524482
pmcid: 4747205
doi: 10.18632/oncotarget.5788
Manier S, Park J, Capelletti M, Bustoros M, Freeman SS, Ha G, et al. Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma. Nat Commun. 2018;9:1691.
pubmed: 29703982
pmcid: 5923255
doi: 10.1038/s41467-018-04001-5
Lee S-Y, Chae D-K, An J, Jung S, Chae CH, Bhak J, et al. Comprehensive mutation profiling of both cfDNA and CTCs in gynecological cancer patients. bioRxiv. 2019:566786.
Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24.
pubmed: 24553385
pmcid: 4017867
doi: 10.1126/scitranslmed.3007094
Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Disco. 2014;4:650–61.
doi: 10.1158/2159-8290.CD-13-1014
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
pubmed: 21376230
doi: 10.1016/j.cell.2011.02.013
Freidin MB, Freydina DV, Leung M, Montero Fernandez A, Nicholson AG, Lim E. Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies. Clin Chem. 2015;61:1299–304.
pubmed: 26272233
doi: 10.1373/clinchem.2015.242453
Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368:1199–209.
pubmed: 23484797
doi: 10.1056/NEJMoa1213261
Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancer. Nat Rev Cancer. 2018;18:269–82.
pubmed: 29497144
doi: 10.1038/nrc.2018.11
Liebs S, Keilholz U, Kehler I, Schweiger C, Haybäck J, Nonnenmacher A. Detection of mutations in circulating cell-free DNA in relation to disease stage in colorectal cancer. Cancer Med. 2019;8:3761–9.
pubmed: 31134762
pmcid: 6639174
doi: 10.1002/cam4.2219
Salvianti F, Pinzani P, Verderio P, Ciniselli CM, Massi D, De Giorgi V, et al. Multiparametric analysis of cell-free DNA in melanoma patients. PLoS One. 2012;7:e49843.
pubmed: 23209607
pmcid: 3507877
doi: 10.1371/journal.pone.0049843
Mazurek AM, Rutkowski T, Fiszer-Kierzkowska A, Małusecka E, Składowski K. Assessment of the total cfDNA and HPV16/18 detection in plasma samples of head and neck squamous cell carcinoma patients. Oral Oncol. 2016;54:36–41.
pubmed: 26786940
doi: 10.1016/j.oraloncology.2015.12.002
Lebofsky R, Decraene C, Bernard V, Kamal M, Blin A, Leroy Q, et al. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol Oncol. 2015;9:783–90.
pubmed: 25579085
doi: 10.1016/j.molonc.2014.12.003
Kidess E, Heirich K, Wiggin M, Vysotskaia V, Visser BC, Marziali A, et al. Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform. Oncotarget. 2015;6:2549–61.
pubmed: 25575824
doi: 10.18632/oncotarget.3041
Lin SY, Huang SK, Huynh KT, Salomon MP, Chang S-C, Marzese DM, et al. Multiplex gene profiling of cell-free DNA in patients with metastatic melanoma for monitoring disease. JCO Precis Oncol. 2018;2:1–30.
pubmed: 35135134
Galot R, van Marcke C, Helaers R, Mendola A, Goebbels RM, Caignet X, et al. Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic head and neck squamous cell carcinoma. Oral Oncol. 2020;104:104631.
pubmed: 32169746
doi: 10.1016/j.oraloncology.2020.104631
Wang Y, Springer S, Mulvey CL, Silliman N, Schaefer J, Sausen M, et al. Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci Transl Med. 2015;7:293ra104.
pubmed: 26109104
pmcid: 4587492
doi: 10.1126/scitranslmed.aaa8507
Hristozova T, Konschak R, Stromberger C, Fusi A, Liu Z, Weichert W, et al. The presence of circulating tumor cells (CTCs) correlates with lymph node metastasis in nonresectable squamous cell carcinoma of the head and neck region (SCCHN). Ann Oncol. 2011;22:1878–85.
pubmed: 21525401
doi: 10.1093/annonc/mdr130
Khoja L, Lorigan P, Zhou C, Lancashire M, Booth J, Cummings J, et al. Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. J Invest Dermatol. 2013;133:1582–90.
pubmed: 23223143
doi: 10.1038/jid.2012.468
Cayrefourcq L, De Roeck A, Garcia C, Stoebner P-E, Fichel F, Garima F, et al. S100-EPISPOT: a new tool to detect viable circulating melanoma cells. Cells. 2019;8:755.
pmcid: 6678250
doi: 10.3390/cells8070755
Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:3213–21.
pubmed: 18591556
doi: 10.1200/JCO.2007.15.8923
Genna A, Vanwynsberghe AM, Villard AV, Pottier C, Ancel J, Polette M, et al. EMT-associated heterogeneity in circulating tumor cells: sticky friends on the road to metastasis. Cancers (Basel). 2020;12:1632.
Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339:580–4.
pubmed: 23372014
pmcid: 3760262
doi: 10.1126/science.1228522
Pestrin M, Salvianti F, Galardi F, De Luca F, Turner N, Malorni L, et al. Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. Mol Oncol. 2015;9:749–57.
pubmed: 25539732
doi: 10.1016/j.molonc.2014.12.001
Pailler E, Auger N, Lindsay CR, Vielh P, Islas-Morris-Hernandez A, Borget I, et al. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer. Ann Oncol. 2015;26:1408–15.
pubmed: 25846554
pmcid: 4478971
doi: 10.1093/annonc/mdv165
De Luca F, Rotunno G, Salvianti F, Galardi F, Pestrin M, Gabellini S, et al. Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer. Oncotarget. 2016;7:26107–19.
pubmed: 27034166
pmcid: 5041968
doi: 10.18632/oncotarget.8431
Majidpoor J, Mortezaee K. Steps in metastasis: an updated review. Med Oncol. 2021;38:3.
pubmed: 33394200
doi: 10.1007/s12032-020-01447-w
Hu B, Tian X, Li Y, Liu Y, Yang T, Han Z, et al. Epithelial-mesenchymal transition may be involved in the immune evasion of circulating gastric tumor cells via downregulation of ULBP1. Cancer Med. 2020;9:2686–97.
pubmed: 32077634
pmcid: 7163085
doi: 10.1002/cam4.2871
Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, et al. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science. 2015;349:1351–6.
pubmed: 26383955
pmcid: 4872391
doi: 10.1126/science.aab0917
Gorges K, Wiltfang L, Gorges TM, Sartori A, Hildebrandt L, Keller L, et al. Intra-patient heterogeneity of circulating tumor cells and circulating tumor DNA in blood of melanoma patients. Cancers (Basel). 2019;11:1685.
Yap SA, Münster-Wandowski A, Nonnenmacher A, Keilholz U, Liebs S. Analysis of cancer-related mutations in extracellular vesicles RNA by Droplet Digital™ PCR. Biotechniques. 2020;69:99–107.
Onidani K, Shoji H, Kakizaki T, Yoshimoto S, Okaya S, Miura N, et al. Monitoring of cancer patients via next-generation sequencing of patient-derived circulating tumor cells and tumor DNA. Cancer Sci. 2019;110:2590–9.
pubmed: 31169336
pmcid: 6676129
doi: 10.1111/cas.14092
Lack J, Gillard M, Cam M, Paner GP, VanderWeele DJ. Circulating tumor cells capture disease evolution in advanced prostate cancer. J Transl Med. 2017;15:44.
pubmed: 28228136
pmcid: 5322599
doi: 10.1186/s12967-017-1138-3
Eder T, Hess AK, Konschak R, Stromberger C, Johrens K, Fleischer V, et al. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group. Eur J Cancer. 2019;116:67–76.
pubmed: 31173964
doi: 10.1016/j.ejca.2019.04.015
Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019;47:D941–d7.
pubmed: 30371878
doi: 10.1093/nar/gky1015
COSMIC – Catalogue of somatic mutations in cancer. cancer.sanger.ac.uk. 2004. accessed date 17.07.2019.
Tamborero D, Rubio-Perez C, Deu-Pons J, Schroeder MP, Vivancos A, Rovira A, et al. Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations. Genome Med. 2018;10:25.
pubmed: 29592813
pmcid: 5875005
doi: 10.1186/s13073-018-0531-8
Institute for Research in Biomedicine. Cancer Genome Interpreter. 2018. accessed date 17.07.2019. https://www.cancergenomeinterpreter.org .